免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

FDA PMA

Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer

PMA番号：P040008 · 2016-05-31

申請者bioMerieux, Inc.
決定日2016-05-31
PMA番号P040008
製品コードMTF
デバイスクラスクラス3
診療科U
諮問委員会IM

医療機器の概要

Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer is the device name listed in this FDA 510(k) record. The listed applicant is bioMerieux, Inc.. It received FDA 510(k) clearance on 2016-05-31. The device is classified under product code MTF. It was reviewed by the IM advisory panel.

よくある質問

What is the Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer?

Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer is a medical device that received FDA 510(k) clearance on 2016-05-31. The listed applicant is bioMerieux, Inc..

When did Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer receive FDA 510(k) clearance?

The clearance date for Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer can be found in the official FDA records.

Who is the listed applicant for Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer?

The FDA 510(k) record lists bioMerieux, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer?

The FDA product code for Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer is MTF.

関連する臨床試験

関連レコードは、名称、製品コード、その他のメタデータを使用して自動的にマッチングされます。マッチは検証された臨床的、科学的、企業的、または規制上の関係を確立するものではありません。リンクされた公式情報源をご確認ください。

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDEDNCT07095751膀胱癌を診断するための人工知能（AI）アシストドのUro-Camカテーテル評価システムNOT_YET_RECRUITING

公式ソース

FDAデータベースで見る →

データはFDA Open APIから取得しています。最新かつ権威ある情報については、常に公式レコードを参照してください。

↑